Peptide Drug Conjugates: Cancer Research Frontier

For decades, cancer treatment meant carpet-bombing the body with chemotherapy and hoping the tumor took more damage than the patient. Antibody-drug conjugates (ADCs) changed that equation by strapping cytotoxic payloads to tumor-targeting antibodies — but antibodies are large, expensive to manufacture, and often struggle to penetrate solid tumors. Peptide-drug conjugates (PDCs) are emerging as a smaller, cheaper, and potentially more effective alternative. With roughly 96 PDCs now in development and six in Phase III trials, this drug class is generating real clinical data — not just preclinical promise.

This article breaks down what PDCs are, how they work, which candidates are producing results in clinical trials, and where the field is heading.

---

Table of Contents

1. What Are Peptide-Drug Conjugates?
2. PDCs vs. Antibody-Drug Conjugates: Key Differences
3. How PDCs Target Cancer Cells
4. Linker Chemistry: The Make-or-Break Component
5. FDA-Approved PDCs
6. Clinical Pipeline: PDCs in Active Trials
7. Bicycle Toxin Conjugates: A New Subclass
8. Lessons From Failed PDCs
9. The Future: AI Design, Theranostics, and Combination Therapy
10. The Bottom Line
11. References

---

What Are Peptide-Drug Conjugates?

A peptide-drug conjugate is a three-part molecule: a short peptide that homes in on a target (usually a receptor overexpressed on cancer cells), a cytotoxic or radioactive payload, and a chemical linker holding them together. The peptide steers the payload to the tumor. The linker keeps the payload attached during circulation and releases it once the conjugate reaches its target.

Most homing peptides are fewer than 40 amino acids long, giving the entire PDC a molecular weight well under 5 kilodaltons — roughly 30 to 50 times smaller than an antibody-drug conjugate. That size difference matters. Smaller molecules diffuse faster through tissue, penetrate deeper into solid tumors, and clear from the body through the kidneys rather than lingering in circulation.

PDCs sit in a conceptual space between two established drug classes: small-molecule chemotherapy (potent but indiscriminate) and antibody-drug conjugates (targeted but bulky). For readers interested in the broader field of peptides in cancer research, PDCs represent one of the most active frontiers.

PDCs vs. Antibody-Drug Conjugates: Key Differences

By October 2024, 15 ADC drugs had received regulatory approval worldwide. PDCs have only two FDA approvals to date — one of which was withdrawn. But comparing the two classes on approvals alone misses the structural advantages that make PDCs attractive for next-generation development.

Feature	PDCs	ADCs
Molecular weight	< 5 kDa	~150 kDa
Tumor penetration	High (rapid diffusion)	Limited in solid tumors
Immunogenicity	Low	Higher risk
Manufacturing cost	Lower (chemical synthesis)	Higher (biological production)
Drug loading control	Precise, homogeneous	Often heterogeneous
Serum half-life	Short (hours)	Long (days to weeks)
Target specificity	Moderate	High
Clinical maturity	Emerging (~96 in development)	Established (15 approved)

The short half-life cuts both ways. Rapid clearance reduces systemic toxicity but shrinks the window for tumor binding, demanding precise receptor targeting and optimized dosing.

How PDCs Target Cancer Cells

PDCs exploit a basic principle: tumor cells overexpress specific surface receptors. The homing peptide binds one of these receptors, the conjugate gets internalized via endocytosis, and once inside the cell, the linker breaks down to release the toxic payload. The most common targeting strategies include:

Somatostatin receptors (SSTRs). Overexpressed in neuroendocrine tumors. This is the target behind Lutathera, the most successful PDC on the market. The somatostatin analog octreotate directs the radionuclide payload (lutetium-177) straight to SSTR-positive tumor cells.

GnRH/LHRH receptors. Overexpressed in breast (~50%), endometrial (~80%), prostate (~86%), and ovarian (~90%) cancers. The failed-but-instructive zoptarelin doxorubicin targeted this receptor.

Integrin receptors. RGD-containing cyclic peptides can target integrins overexpressed on tumor vasculature and certain cancer cells.

pH-based targeting (receptor-independent). CBX-12, one of the most watched PDCs in development, skips receptor targeting entirely. It uses a pH-Low Insertion Peptide (pHLIP) that selectively inserts into cell membranes in the acidic tumor microenvironment — a strategy that works regardless of receptor expression.

LRP1-mediated transport. ANG1005 uses Angiopep-2 to cross the blood-brain barrier via LRP1, delivering paclitaxel to brain metastases that conventional chemotherapy cannot reach.

For related approaches in cancer diagnostics, see peptide radiotracers in cancer diagnostics.

Linker Chemistry: The Make-or-Break Component

If the peptide is the GPS and the payload is the warhead, the linker is the safety mechanism. Get it wrong, and the payload releases prematurely in the bloodstream — killing healthy cells — or never releases at all, making the drug useless.

PDC linkers fall into two broad categories:

Cleavable Linkers

These break under specific conditions found at the tumor site or inside cancer cells:

• Enzyme-cleavable: Peptide sequences like Val-Cit or Gly-Gly-Phe-Gly are recognized and cut by proteases (cathepsin B, matrix metalloproteinases) concentrated in tumor tissue and lysosomes. This is the most popular clinical design — the Val-Cit-PABC system appears in multiple approved conjugates.
• pH-sensitive: Hydrazone bonds remain stable at blood pH (~7.4) but hydrolyze in the acidic environment of lysosomes (pH 4.8) and late endosomes (pH 5.5-6.2). These work best in hematologic tumors.
• Reducible (disulfide): These exploit the elevated glutathione (GSH) levels in tumor cells — up to four times higher than normal tissue. Disulfide bonds remain stable in blood but reduce in the GSH-rich intracellular environment.

Non-Cleavable Linkers

Thioethers, oximes, and triazole bonds do not respond to enzymatic or environmental triggers. Instead, the payload releases only when the entire conjugate is degraded inside lysosomes. Non-cleavable linkers offer better plasma stability and a wider dosing window but depend entirely on intracellular degradation for drug release.

The failure of zoptarelin doxorubicin in Phase III trials has been partly attributed to linker instability. When researchers replaced the original ester-glutaric acid linker and swapped doxorubicin for MMAE, the redesigned conjugate showed over 100-fold greater potency in ovarian cancer cells (GI50 of 4 nM vs. 453 nM). Linker design is not a detail — it is often the difference between a drug that works and one that does not.

FDA-Approved PDCs

Lutathera (177Lu-DOTATATE) — The Gold Standard

Approved by the FDA in January 2018, Lutathera remains the only PDC with active U.S. marketing authorization. It is a peptide receptor radionuclide therapy (PRRT) that pairs the somatostatin analog octreotate with the beta-emitting isotope lutetium-177.

The landmark NETTER-1 trial enrolled 231 patients with progressive midgut neuroendocrine tumors and produced striking results:

• Progression-free survival: HR 0.18 (95% CI: 0.11-0.29; p < 0.0001). At 20 months, 65.2% of Lutathera patients were progression-free vs. 10.8% on high-dose octreotide alone.
• Overall survival: Median 48.0 months vs. 36.3 months (HR 0.84). The 11.7-month difference did not reach statistical significance (p=0.30), likely confounded by 36% of control patients crossing over to receive radioligand therapy after progression.
• Response rate: 18% vs. 3% (p < 0.001).
• Quality of life: Median time to deterioration was 28.8 months vs. 6.1 months for global health status.

Real-world data from the NETTER-R study in pancreatic neuroendocrine tumors showed a median overall survival of 41.4 months, a median PFS of 24.8 months, and an objective response rate of 40.3% — confirming Lutathera's benefit beyond the original trial population.

Pepaxto (Melflufen) — A Cautionary Tale

Pepaxto received accelerated FDA approval in February 2021 for relapsed/refractory multiple myeloma based on a 23.7% overall response rate in the Phase II HORIZON trial. The concept was clever: melflufen is a highly lipophilic peptide-drug conjugate that enters myeloma cells in the bone marrow, where aminopeptidases cleave the peptide to release a melphalan payload.

But the confirmatory Phase III OCEAN trial told a different story. While melflufen showed a PFS advantage (6.9 vs. 4.9 months), median overall survival was 19.7 months in the melflufen arm vs. 25.0 months with pomalidomide-dexamethasone — a roughly 5-month survival deficit. The FDA withdrew approval in February 2024 after the Oncologic Drugs Advisory Committee voted 14 to 2 that the benefit-risk profile was unfavorable. Melflufen retains marketing authorization in Europe.

Clinical Pipeline: PDCs in Active Trials

Here are the most advanced candidates generating clinical data:

PDC	Target	Payload	Phase	Cancer Type	Developer
ANG1005	LRP1 (BBB crossing)	Paclitaxel (x3)	Phase III	Breast cancer brain mets	Angiochem
CBX-12	pH (receptor-independent)	Exatecan (TOP1i)	Phase II	Ovarian, solid tumors	Cybrexa
BT8009	Nectin-4	MMAE	Phase II/III	Urothelial carcinoma	Bicycle Therapeutics
BT5528	EphA2	MMAE	Phase I/II	Solid tumors (UC, ovarian)	Bicycle Therapeutics
G202	PSMA	Thapsigargin	Phase II	Prostate, renal, liver, glioma	GenSpera
AVA6103	FAP	Exatecan	Phase I (2026)	Solid tumors	Avacta

ANG1005: Crossing the Blood-Brain Barrier

Brain metastases from breast cancer are notoriously difficult to treat because conventional chemotherapy cannot cross the blood-brain barrier effectively. ANG1005 addresses this by conjugating three paclitaxel molecules to Angiopep-2, a 19-amino-acid peptide that crosses into the brain via LRP1-mediated transcytosis.

Phase II data in 72 breast cancer patients with brain metastases showed intracranial clinical benefit (stable disease or better) in 77% and extracranial benefit in 86%. These patients had received an average of 2.8 prior CNS-directed therapies, and 94% had failed prior taxane treatment — making the responses particularly notable. In vivo, ANG1005 delivers 4 to 54 times more drug to brain tissue than free paclitaxel.

The Phase III ANGLeD trial (NCT03613181) is comparing ANG1005 to physician's best choice in HER2-negative breast cancer with leptomeningeal disease. Results have not yet been reported.

CBX-12: Targeting Acidity, Not Receptors

Most PDCs require the target tumor to express a specific receptor at high levels. CBX-12 takes a fundamentally different approach. It uses Cybrexa's alphalex platform, built on pH-Low Insertion Peptide (pHLIP) technology, to deliver exatecan — a potent topoisomerase 1 inhibitor — to any tumor with an acidic microenvironment. Since acidity is a near-universal feature of solid tumors, this strategy could theoretically work across cancer types regardless of receptor expression.

Phase I data presented at ESMO 2024 showed activity across six tumor types. In TOP1-naive ovarian cancer patients (n=10), the response rate was 40%, including one complete response. In HR+/HER2- breast cancer (n=7), the rate hit 43%. Notably, no cases of interstitial lung disease or ophthalmic toxicity — common problems with ADCs — were reported.

The first patient was dosed in a Phase II randomized trial in platinum-resistant ovarian cancer in October 2024. Cybrexa is also planning a Phase II trial in colorectal cancer in collaboration with the National Cancer Institute, plus additional studies of its next-generation conjugate CBX-15 (carrying an MMAE payload) expected to enter the clinic in 2025.

Bicycle Toxin Conjugates: A New Subclass

Bicycle Therapeutics has developed a distinct PDC subclass using constrained bicyclic peptides — small, synthetic peptides locked into two interlocking rings by a chemical scaffold. These molecules combine the target specificity of antibodies with the tissue penetration of small molecules, and at roughly 1.5-2 kDa, they are even smaller than typical linear peptide conjugates.

BT8009 (Zelenectide Pevedotin)

BT8009 targets Nectin-4, the same receptor targeted by the ADC enfortumab vedotin (Padcev) in urothelial cancer. But BT8009 is dramatically smaller, with a half-life of just 1-2 hours vs. days for the ADC — which may translate to less systemic toxicity.

Clinical results have been striking. In the Duravelo-1 Phase I/II study:

• Monotherapy: 49 patients enrolled, mostly with urothelial carcinoma. One patient with metastatic UC achieved a near-complete response after two cycles and a confirmed complete response after four cycles, maintained for over 18 months.
• Combination with pembrolizumab (ASCO 2025): In 20 evaluable cisplatin-ineligible first-line urothelial cancer patients, the overall response rate was 65% (95% CI: 40.8-84.6%), including 25% complete responses and 40% partial responses. Disease control rate hit 90%.

BT8009 received FDA Fast Track Designation and has advanced to the Phase II/III Duravelo-2 trial (NCT06225596).

BT5528

BT5528 targets EphA2, a receptor overexpressed in ovarian, urothelial, lung, and breast cancers. In updated Phase I/II data presented at ESMO 2024 (128 patients), the overall response rate was 12% across all solid tumor types. But in metastatic urothelial cancer specifically, the rate climbed to 34% across dose levels and 45% in the expansion cohort at the recommended Phase II dose (6.5 mg/m2 Q2W). Combination studies with nivolumab began in 2025.

For more on how cell-penetrating peptides facilitate drug delivery in cancer research, see our dedicated overview.

Lessons From Failed PDCs

The failures have been as informative as the successes.

Zoptarelin doxorubicin (AEZS-108) targeted GnRH receptors — overexpressed in prostate, ovarian, endometrial, and breast cancers — to deliver doxorubicin. Preclinical data showed 90.5% tumor growth inhibition in mouse models. Phase II trials earned it FDA orphan drug designation. But the Phase III trial in endometrial cancer found no improvement in survival vs. doxorubicin alone, and the program was discontinued in May 2017. Post-hoc analyses point to an unstable ester-glutaric acid linker and insufficient payload potency. When researchers replaced both the linker and the payload (swapping doxorubicin for MMAE), bioactivity jumped over 100-fold.

Melflufen's withdrawal (discussed above) reinforced a different lesson: response rate does not guarantee overall survival. The OCEAN trial showed the drug could shrink tumors, but patients lived shorter lives.

These failures highlight three recurring themes: linker stability is non-negotiable, payload potency matters as much as targeting, and surrogate endpoints can mislead.

The Future: AI Design, Theranostics, and Combination Therapy

AI-Optimized PDCs

The PDCdb database — cataloging biological activity data for over 2,036 PDCs — reports that 78% of PDCs entering clinical trials since 2022 have utilized AI-optimized components, up from less than 15% before 2020. Deep learning frameworks like RFdiffusion can now generate de novo cyclic peptides with 60% higher tumor affinity compared to traditional phage-display methods. Reinforcement learning platforms have achieved 85% payload release specificity in tumor microenvironments — roughly double the rate of conventional hydrazone linkers.

Theranostic PDCs

The same peptide that delivers a therapeutic payload can also carry a diagnostic isotope. Lutathera's success in neuroendocrine tumors opened the door for "theranostic pairs" — using gallium-68-DOTATATE for PET imaging to identify patients whose tumors express the target, then treating with lutetium-177-DOTATATE. This select-then-treat approach is now being explored across other PDC platforms, including Bicycle Therapeutics' development of EphA2-targeting radiopharmaceuticals with first human imaging data expected in the second half of 2025.

Combination Strategies

The BT8009/pembrolizumab combination data (65% ORR in first-line urothelial cancer) suggest PDCs may pair powerfully with checkpoint inhibitors. The rationale: PDCs deliver cytotoxic payloads that can trigger immunogenic cell death, potentially "priming" the immune system to respond better to immunotherapy. Multiple peptide vaccine and PDC-immunotherapy combinations are now in early-stage trials.

Overcoming Pharmacokinetic Limitations

Rapid renal clearance remains the central PDC challenge. Strategies to extend half-life include peptide cyclization, D-amino acid substitution, PEGylation, albumin-binding modifications, and bicyclic peptide scaffolds. The semaglutide guide offers a relevant case study: semaglutide achieves a seven-day half-life through albumin binding and protease resistance — techniques now being adapted for PDC development.

The Bottom Line

PDCs occupy a promising middle ground in targeted cancer therapy — smaller and cheaper than ADCs, more targeted than traditional chemotherapy. The field has one clear clinical success (Lutathera), one instructive failure (melflufen), and a pipeline of roughly 96 candidates producing increasingly compelling data.

The numbers that matter: BT8009 produced a 65% response rate combined with pembrolizumab in first-line urothelial cancer. CBX-12 showed 40% in platinum-resistant ovarian cancer via receptor-independent pH targeting. BT5528 hit 45% in metastatic urothelial cancer at the recommended Phase II dose. ANG1005 achieved 77% clinical benefit in brain metastases that had failed nearly three prior CNS-directed therapies.

None of these come from Phase III randomized trials yet, and history teaches that early-phase promise does not always survive confirmatory studies. But the diversity of approaches — receptor-targeted, pH-targeted, blood-brain barrier-penetrating, theranostic — suggests this drug class has staying power. The question is no longer whether PDCs can work. It is which designs, targets, and combinations will produce durable survival benefits.

Phase III readouts from ANG1005, BT8009, and others over the next two to three years will define whether PDCs deliver on their early promise.

---

References

1. Armstrong, M. et al. (2025). Peptide-Drug Conjugates: A New Hope for Cancer. Journal of Peptide Science. PMC12254541

2. Parang, K. et al. (2026). Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress. Drug Design, Development and Therapy, Dove Press. Full text

3. Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)? (2025). Journal of Nanobiotechnology. Full text

4. Fu, C. et al. (2023). Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharmaceutica Sinica B. PMC9978859

5. Strosberg, J. et al. (2017). Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 376, 125-135. Full text

6. Strosberg, J. et al. (2021). 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results. The Lancet Oncology. PubMed

7. Pavel, M. et al. (2025). Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the NETTER-1 Trial. Cancer Medicine. PMC12020026

8. Kumthekar, P. et al. (2020). ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clinical Cancer Research, 26(12), 2789-2799. Full text

9. Cybrexa Therapeutics. (2024). Positive Final Data from Phase 1 Study of CBX-12 in Advanced Solid Tumors Presented at ESMO 2024. Press release

10. Shih, K. et al. (2024). Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. PubMed

11. Giannatempo, P. et al. (2025). Phase 1/2 Duravelo-1 Study: Preliminary Results of Zelenectide Pevedotin (BT8009) plus Pembrolizumab in Urothelial Cancer. Presented at ASCO 2025. Summary

12. Jessee, J.K. (2022). Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Annals of Pharmacotherapy. PubMed

13. FDA Confirms Decision to Withdraw Melphalan Flufenamide Approval in Multiple Myeloma (2024). OncLive

14. PDCdb: the biological activity and pharmaceutical information of peptide-drug conjugate (PDC). (2025). Nucleic Acids Research, 53(D1), D1476. Full text

15. First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. (2025). Journal of Clinical Oncology. Full text

16. He, R. et al. (2019). Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules, 24(10), 1855. PMC6572008

17. Trends in the research and development of peptide drug conjugates: artificial intelligence aided design. (2025). Frontiers in Pharmacology. Full text

Last updated: February 2026. This article is for educational purposes only and does not constitute medical advice. Discuss any treatment decisions with a qualified healthcare provider.